Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multi-center, Observational Study of the Safety, Tolerability and Effectiveness of SPINRAZA® (Nusinersen) in Adult Patients With Spinal Muscular Atrophy

NCT03709784 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT03709784
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03709784 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multi-center, Observational Study of the Safety, Tolerability and Effectiveness of SPINRAZA® (Nusinersen) in Adult Patients With Spinal Muscular Atrophy
Lead sponsor
Washington University School of Medicine
Phase
Observational
Overall status
Active, not recruiting
Start date
August 16, 2018
Completion date
January 1, 2025
Enrollment
148 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

spinal muscular atrophy, spinal muscular atrophy type 3, spinal muscular atrophy type ii